DIA/FDA Oligonucleotide-Based Therapeutic Conference 2015

Interact with renowned investigators and key health authorities to learn about the latest developments in oligonucleotide-based therapeutics. New for 2015—Enhanced poster session.

返回 Agendas

Session 9BC: Non Clinical and Clinical Track Combination: Thrombocytopenia – OSWG

Session Chair(s)

Scott Henry, PHD

Senior Vice President, Nonclinical Development

Ionis Pharmaceuticals, Inc., United States

Robert T. Dorsam, PHD

Associate Director, Pharmacology/Toxicology, Office of Generic Drugs, CDER

FDA, United States

Nonclinical data from nonhuman primates as well as translational data will be discussed in this session. The central questions to be addressed are: • What mechanism(s) are central to clinical thrombocytopenia associated with oligonucleotide administration?
• If clinical thrombocytopenia occurs, what incidence and severity constitute a problem?

Speaker(s)

Progress in Understanding the Mechanism of ASO-Mediated Platelet Decrease in Non-human Primates

Padma Narayanan

Ionis Pharmaceuticals, Inc., United States

Executive Director, Toxicology

Speaker Invited

United States

Panel Discussion

All Session Speakers, United States